#flexiontherapeutics Archives - Orthopedics This Week

Company News

In $425M Deal, Pacira BioSciences to Buy Flexion Therapeutics

by Kim DelMonico October 26, 2021November 1, 2024

Company News

Zilretta Knee Injection Sales Up 82% for June Quarter

by Kim DelMonico August 25, 2021November 1, 2024

Large Joints and Extremities

Flexion Reports Impressive Q1 Sales and Updated Clinical Data

by Kim DelMonico June 3, 2021November 1, 2024

Sports Medicine

WNBA Legend Sheryl Swoopes Teams Up With Flexion Therapeutics

by Tracey Romero February 19, 2021November 1, 2024

Company News

ZILRETTA Beats Analysts’ Projections

by Kim DelMonico January 27, 2021November 1, 2024

Large Joints and Extremities

Key Trial of Novel OA Gene Therapy Advances

by Elizabeth Hofheinz, M.P.H., M.Ed. September 16, 2020November 1, 2024

Company News

This Product’s Sales INCREASED During Pandemic

by Kim DelMonico July 27, 2020November 1, 2024

Company News

Flexion Therapeutics Raises $90MM in a Tough Market

by Adam Suhy, Ph.D. June 8, 2020November 1, 2024

Large Joints and Extremities

72-Hour Knee Analgesic (NaV1.7) Shows Early Promise

by Tracey Romero May 2, 2020November 1, 2024

Company News

Flexion Licenses Extended Release Corticosteroid for China

by Kim DelMonico April 15, 2020November 1, 2024

Large Joints and Extremities

Extended Release Corticosteroid for Knee OA Pain

by Kim DelMonico April 14, 2020November 1, 2024

Company News

COVID Interrupting Clinical Trials, Like This One

by Kim DelMonico April 9, 2020November 1, 2024

Extremities, General Topics, Large Joints and Extremities

Extended-Release Corticosteroid Study for Shoulder OA Begins

by Elizabeth Hofheinz, M.P.H., M.Ed. January 28, 2020November 1, 2024

Sports Medicine

How Athletes Respond to Extended Release Corticosteroids

by Kim DelMonico January 16, 2020October 24, 2024

Legal & Regulatory and Reimbursement

Zilretta Label Update Clears Up Repeated Use Confusion

by Walter Eisner January 15, 2020November 1, 2024

Large Joints and Extremities, Spine

Flexion Acquires Investigational NaV1.7 Inhibitor for Postop Pain

by Elizabeth Hofheinz, M.P.H., M.Ed. September 13, 2019November 1, 2024

Large Joints and Extremities

Time to Switch to an Extended Release Corticosteroid

by Robin Young January 9, 2019January 11, 2019

Large Joints and Extremities

Knee Osteoarthritis: Overview of Current and Evolving Treatment

by Michael Clayman, M.D., Guest Author November 2, 2018October 24, 2024

Tag: #flexiontherapeutics

In $425M Deal, Pacira BioSciences to Buy Flexion Therapeutics

Zilretta Knee Injection Sales Up 82% for June Quarter

Flexion Reports Impressive Q1 Sales and Updated Clinical Data

WNBA Legend Sheryl Swoopes Teams Up With Flexion Therapeutics

ZILRETTA Beats Analysts’ Projections

Key Trial of Novel OA Gene Therapy Advances

This Product’s Sales INCREASED During Pandemic

Flexion Therapeutics Raises $90MM in a Tough Market

72-Hour Knee Analgesic (NaV1.7) Shows Early Promise

Flexion Licenses Extended Release Corticosteroid for China

Extended Release Corticosteroid for Knee OA Pain

COVID Interrupting Clinical Trials, Like This One

Extended-Release Corticosteroid Study for Shoulder OA Begins

How Athletes Respond to Extended Release Corticosteroids

Zilretta Label Update Clears Up Repeated Use Confusion

Flexion Acquires Investigational NaV1.7 Inhibitor for Postop Pain

Time to Switch to an Extended Release Corticosteroid

Knee Osteoarthritis: Overview of Current and Evolving Treatment

The Promise of Biomimetic Implant Surfaces & Nano + Femtosecond Laser Texturing

Sign up for an OTW Subscription

Sign up for Orthopedics This Week

About OTW

Sections

More